- Home
- ZBIO vs SAR Comparison
ZBIO vs SAR Comparison
Compare ZBIO & SAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBIO
- SAR
- Stock Information
- Founded
- ZBIO 2019
- SAR 2007
- Country
- ZBIO United States
- SAR United States
- Employees
- ZBIO N/A
- SAR N/A
- Industry
- ZBIO
- SAR Investment Managers
- Sector
- ZBIO
- SAR Finance
- Exchange
- ZBIO NYSE
- SAR Nasdaq
- Market Cap
- ZBIO 389.2M
- SAR 337.6M
- IPO Year
- ZBIO 2024
- SAR 2007
- Fundamental
- Price
- ZBIO $9.80
- SAR $24.31
- Analyst Decision
- ZBIO Strong Buy
- SAR Buy
- Analyst Count
- ZBIO 7
- SAR 4
- Target Price
- ZBIO $32.29
- SAR $25.08
- AVG Volume (30 Days)
- ZBIO 131.3K
- SAR 115.5K
- Earning Date
- ZBIO 05-15-2025
- SAR 05-07-2025
- Dividend Yield
- ZBIO N/A
- SAR 13.48%
- EPS Growth
- ZBIO N/A
- SAR 186.33
- EPS
- ZBIO N/A
- SAR 2.02
- Revenue
- ZBIO $15,000,000.00
- SAR $148,855,238.00
- Revenue This Year
- ZBIO N/A
- SAR N/A
- Revenue Next Year
- ZBIO N/A
- SAR N/A
- P/E Ratio
- ZBIO N/A
- SAR $12.20
- Revenue Growth
- ZBIO N/A
- SAR 3.57
- 52 Week Low
- ZBIO $5.83
- SAR $21.10
- 52 Week High
- ZBIO $26.25
- SAR $26.49
- Technical
- Relative Strength Index (RSI)
- ZBIO N/A
- SAR 49.07
- Support Level
- ZBIO N/A
- SAR $24.47
- Resistance Level
- ZBIO N/A
- SAR $24.92
- Average True Range (ATR)
- ZBIO 0.00
- SAR 0.33
- MACD
- ZBIO 0.00
- SAR -0.02
- Stochastic Oscillator
- ZBIO 0.00
- SAR 35.29
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
About SAR Saratoga Investment Corp New
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests primarily in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.